[Development of research for drug-resistance mechanism of taxol].
The resistant problem is the main restriction factor for clinical usage of taxol. The main mechanism of its resistance includes the high expression of P-gp, beta- and alpha-tubulin isotypes, the alteration expression of PKC, Bcl-2, p53, and ErbB2. The reversing method includes the use of analogues of taxol to reduce the expression of P-gp, or the use of antibody, immunotoxin, antisence oligonucleotide, and liposomes. The combination with other drugs can also be a method to reverse the resistance of taxol.
Wang
Fang
F
Institute of Materia Medica, CAMS, Beijing 100050.
Han
Rui
R
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols; D017209:Apoptosis; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology; D017239:Paclitaxel / Q000494:pharmacology*; D014404:Tubulin / Q000378:metabolism*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000972:Antineoplastic Agents, Phytogenic; D000922:Immunotoxins; D020319:Oligodeoxyribonucleotides, Antisense; D014404:Tubulin; D017239:Paclitaxel